1. Figure 6 Schematic of an analysis of a new biopsy
sample in relation to a reference set of samples from indication biopsies
Figure 6 | Schematic of an analysis of a new biopsy sample in relation to a reference set of samples from indication biopsies. Each symbol represents one of 530 biopsy samples from a reference set (the details of which have been published46). The samples are coloured by their histologic diagnosis but distributed by their molecular features as determined using principal component analysis. The principal component analysis is based on four molecular classifier scores (T cell-mediated rejection (TCMR), antibody-mediated rejection (ABMR), all rejection and tubular atrophy and interstitial fibrosis (TA/IF)), and the transcript scores for parenchymal and acute kidney injury (AKI). ABMR cases are distributed in the top half of the graph, TCMR on the lower right, and normal cases on the left side. The biopsy sample of interest (yellow triangle) has a histologic diagnosis of ABMR. Prognosis (survival) can be predicted based on the actual outcomes of cases that share the highest molecular similarity to this sample in the Reference Set. In this example, the nearest neighbours to the sample biopsy had ABMR-related conventional and molecular phenotypes; only 43% of patients with this pattern had functioning kidneys at 3 years post biopsy. BK, BK polyomavirus; GN, glomerulonephritis; PC1, principal component 1 (accounts for 47% of total molecular variance in the reference set); PC2, principal component 2 (accounts for 21% of total molecular variance in the reference set); TG, transplant glomerulopathy.
Halloran, P. F. et al. (2016) Molecular assessment of disease states in kidney transplant biopsy samples
Nat. Rev. Nephrol. doi: /nrneph